Home
About Us
Company Overview
Mission
Leadship
Milestones
Science
Technology Platforms
Research Areas
Pipeline
Partnerships
News
News
Contact Us
EN
中文
EN
Home
About Us
Science
Technology Platforms
Research Areas
Pipeline
Partnerships
News
News
Contact Us
News
News
News
01-30
2023
Sciwind Biosciences Announces Initiation of Patient Dosing in Phase 3 Clinical Trials of Ecnoglutide (XW003), a Long-acting GLP-1 analog, for the Treatment of Type 2 Diabetes in China
2023-01-30
10-27
2022
Sciwind Biosciences Announces Positive Interim Results from Ongoing Phase 2b Clinical Trial of XW003 (Ecnoglutide) in Patients with Obesity
2022-10-27
10-09
2022
Sciwind Biosciences Announces Initiation of Dosing in Phase 1 Clinical Trial Evaluating XW014, an oral small molecule GLP-1 receptor agonist for the Treatment of Obesity and Type 2 Diabetes
2022-10-09
09-26
2022
Sciwind Biosciences and SynerK Enter into Research Partnership to Discover and Develop Novel siRNA Therapeutics
2022-09-26
08-08
2022
Sciwind Biosciences Reports Positive Interim Results from Phase 1c/2a Clinical Trial of XW003 (Ecnoglutide) in Overweight and Obese Adult Volunteers in China
2022-08-08
08-02
2022
Sciwind Biosciences Announces Positive Topline Results from 20-week Phase 2 Clinical Trial of XW003 (Ecnoglutide), a novel long-lasting GLP-1 analogue, in Adult Patients with Type 2 Diabetes in China
2022-08-02
<
1
2
3
4
5
>
